Top Suppliers:I want be here
Related CAS#:
88755-39-9 88755-23-1
6266-64-4 51116-24-6
6935-71-3 81258-53-9
41303-68-8 149498-94-2
70770-04-6 84609-13-2

88755-39-9

88755-39-9 structure
88755-39-9 structure
  • Name: 2,4-dibenzo[1,3]dioxol-5-yl-4-oxo-butanoic acid
  • Chemical Name: 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid
  • CAS Number: 88755-39-9
  • Molecular Formula: C18H14O7
  • Molecular Weight: 342.30000
  • Catalog: Research Areas Cancer
  • Create Date: 2017-08-21 02:53:41
  • Modify Date: 2024-01-16 16:30:11
  • RUNX1/ETO tetramerization-IN-1 is a small-molecule inhibitor of RUNX1/ETO tetramerization, exhibits anti-leukemic effect. RUNX1/ETO tetramerization-IN-1 specifically targets to NHR2 of RUNX1/ETO (EC50=0.25 μM), restores gene expression down-regulated by RUNX1/ETO. RUNX1/ETO tetramerization-IN-1 inhibits the proliferation of RUNX1/ETO-depending SKNO-1 cells, and reduces the RUNX1/ETO-related tumor growth in a mouse model[1][2][3].
Name 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid
Synonyms 2,4-Bis-aziridin-1-yl-6-chlor-pyrimidin
Ethymidine
Aethimidinum
2,4-Diethylenimino-6-chloropyrimidine
2,4-bis-aziridin-1-yl-6-chloro-pyrimidine
Etimidin
Ethimidine
2,6-Diethylenimino-4-chloropyrimidine
Aethimidinium
Description RUNX1/ETO tetramerization-IN-1 is a small-molecule inhibitor of RUNX1/ETO tetramerization, exhibits anti-leukemic effect. RUNX1/ETO tetramerization-IN-1 specifically targets to NHR2 of RUNX1/ETO (EC50=0.25 μM), restores gene expression down-regulated by RUNX1/ETO. RUNX1/ETO tetramerization-IN-1 inhibits the proliferation of RUNX1/ETO-depending SKNO-1 cells, and reduces the RUNX1/ETO-related tumor growth in a mouse model[1][2][3].
Related Catalog
Target

IC50: 630 μM (RUNX1-NHR2 tetramerization)[1]
In Vitro RUNX1/ETO is composed by the DNA-binding Runt-domain5, the product of the RUNX1 gene, and by four nervy homology regions (NHR1-4), the product of the ETO gene. The NHR2 domain is responsible for the tetramerization of RUNX1/ETO. RUNX1/ETO tetramerization-IN-1 (compound 7.44) (1 μM and 10 μM; 3, 5, 7 d) selectively reduces the viability of RUNX1/ETO-dependent human leukemic SKNO-1 cells instead of U937 cells[1]. RUNX1/ETO tetramerization-IN-1 (compound 7.44) (25 μM and 50 μM; 5 d) inhibits the growth of and induces myeloid differentiation in RUNX1/ETO-expressing cells (SKNO-1, Kasumi-1, and K562)[2]. RUNX1/ETO tetramerization-IN-1 (100 μM; 7 d) induces growth-arrest and differentiation of RUNX1/ETOtr-expressing CD34+ progenitor cells[2]. RUNX1/ETO tetramerization-IN-1 (compound 7.44) has favorable physicochemical and ADME properties with high aqueous solubility, high stability in buffer and plasma, and a low hepatic intrinsic clearance in vitro, with the aqueous solubility of 60 μg/mL[3]. RUNX1/ETO tetramerization-IN-1 (1 μM and 10 μM) shows a potential to inhibit CYP2B6, 2C9, 2C19, and 3A4[3]. RUNX1/ETO tetramerization-IN-1 (compound 8) (50 μM; 16 h) inhibits c-Jun N-terminal kinase (JNK) and affect the JNK-pathway in cells[4]. Cell Viability Assay[1] Cell Line: RUNX1/ETO-dependent human leukemic SKNO-1 and U937 cells Concentration: 1 μM and 10 μM Incubation Time: 3, 5, 7 days Result: Inhibited the SKNO-1 cell growth specifically. Cell Viability Assay[3] Cell Line: Pharmacokinetic properties of RUNX1/ETO tetramerization-IN-1 Concentration: Incubation Time: Result: Kinetic solubility (99% PBS, 1% DMSO) 177 µM Plasma protein binding (mouse plasma, 60 min) 98.4% Plasma stability (mouse plasma, 0–240 min) No degradation Hepatocyte stability (mouse hepatocytes) 2.5 µL/min/million cells Chemical stability in PBS (0–4 h) No degradation
In Vivo RUNX1/ETO tetramerization-IN-1 (compound 7.44) (200-250 μg/kg; i.p.; 5 times per week; 130 d) delays tumor growth of RUNX1/ETO cells in mice[2]. Animal Model: NSG immunodeficient mice (NOD.Cg-Prkdcscid Il2rgtm1WjI/SzJ) injected with Kasumi-1 cells[2] Dosage: 200-250 μg/Kg Administration: Intraperitoneal injection; 5 times per week, for 130 days Result: Reduced the dissemination of leukemic cells, remained 75% mice alive at day 130 post-treatment.
References

[1]. Metz A, et al. From determinants of RUNX1/ETO tetramerization to small-molecule protein-protein interaction inhibitors targeting acute myeloid leukemia. J Chem Inf Model. 2013 Sep 23;53(9):2197-202. 

[2]. Schanda J, et al. Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization. Haematologica. 2017 May;102(5):e170-e174.

[3]. Gopalswamy M, et al. Biophysical and pharmacokinetic characterization of a small-molecule inhibitor of RUNX1/ETO tetramerization with anti-leukemic effects. Sci Rep. 2022 Aug 19;12(1):14158. 

[4]. Kaoud TS, et al. From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules. ACS Med Chem Lett. 2012 Aug 6;3(9):721-725.

Density 1.472g/cm3
Boiling Point 598.6ºC at 760 mmHg
Molecular Formula C18H14O7
Molecular Weight 342.30000
Flash Point 223.2ºC
Exact Mass 342.07400
PSA 91.29000
LogP 2.58520
Index of Refraction 1.641
88755-23-1 structure

88755-23-1

~%

88755-39-9 structure

88755-39-9
Literature: Ishii; Kawanabe; Harada; et al. Chemical and Pharmaceutical Bulletin, 1983 , vol. 31, # 9 p. 3039 - 3055
Precursor  1

DownStream  1


Chemsrc provides CAS#:88755-39-9 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 88755-39-9 | Chemsrc address: https://m.chemsrc.com/en/baike/593599.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved